BioAlign Inc.

BioAlign Inc. develops patient-specific, growth-driven implant technology for the treatment of early-onset scoliosis (EOS) in pediatric patients. The company's core innovation addresses a significant clinical need: current standard-of-care scoliosis correction procedures carry a 30–50% complication rate requiring revision surgery. BioAlign's proprietary technology platform includes self-actuating growth rods, patient-specific distraction procedures, and growth data monitoring systems designed to enable physiologic spine growth while correcting deformity, thereby reducing revision surgery rates and improving long-term patient outcomes. The company targets the approximately 40,000 annual pediatric scoliosis correction surgeries performed in the United States, where 3 million children have been diagnosed with the condition. BioAlign's leadership team brings cumulative experience exceeding 100 years in spine implant product development, FDA regulatory approval, and commercialization across major spinal implant manufacturers. The company holds 16+ granted patents across 7 countries and is actively raising capital for commercialization. Products are designed for use by orthopedic and spine surgeons in hospital operating rooms and specialized spine surgery centers.